Ceapro Licenses an Innovative Process Technology From University of Alberta

Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or "the Company") is very pleased to
announce the signing of a Licensing and Development Agreement with the
University of Alberta for the rights related to a technology entitled:
"Formation of Micro/Nanoparticles and Encapsulation of Bioactives Using
Supercritical Fluid Technology." 


"The signing of this Agreement is a significant milestone for our Company since
this technology would allow the development, production and commercialization of
powder formulations that could be used as active ingredients in large markets
like functional food, nutraceuticals and pharmaceuticals, a vision that we have
expressed over the last two years," said Gilles Gagnon, President and CEO of
Ceapro. "This partnership between Ceapro and the University of Alberta is a
great example of translational research from lab to market," he added.


"This project exemplifies the high level of innovation happening at the
University of Alberta," said Mr. Chris Lumb, CEO of TEC Edmonton, which is the
University's licensing agent. "This agreement will create jobs and export
revenue. It also demonstrates the importance of local licensing as a way to
develop economic diversity, and to increase linkages between universities and
their communities. We're very pleased to have a continuing relationship with
Ceapro." 


"It is very gratifying to see the technology developed in my lab together with
my former PhD student, Dr. Bernhard Seifried with funding from NSERC-Discovery
Grants program and Alberta Ingenuity Scholarship to be scaled up and
commercialized by Ceapro," said Dr. Feral Temelli, Professor of Food Process
Engineering. 


About the Technology

This Technology was invented by Dr. Temelli from the Department of Agricultural,
Food & Nutritional Science of the University of Alberta along with Dr. Bernhard
Seifried, now Senior Researcher at Ceapro.


The technology is called "PGX Technology", a novel spray drying technique for
processing water-soluble biopolymers, including oat beta glucan, utilizing the
unique and tuneable properties of Pressurized Gas eXpanded liquids. PGX
Technology is a platform that can produce numerous morphologies of biopolymers
ranging from fine fibres to granular powder, which are highly water soluble and
could find commercial success in a wide range of industries including functional
foods, nutraceuticals, cosmeceuticals, and pharmaceutical products. This
technology operates at lower temperatures than conventional spray drying
allowing incorporation of thermosensitive bioactives as well.


About Ceapro Inc.

Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business
activities relate to the development and commercialization of active ingredients
for healthcare and cosmetic industries using proprietary technology and natural,
renewable resources. To learn more about Ceapro, visit www.ceapro.com. 


About TEC Edmonton 

TEC Edmonton helps tech entrepreneurs accelerate their growth. In addition to
being the commercialization agent for University of Alberta technologies, TEC
Edmonton operates the region's largest incubator for early stage technology
companies, including both university spinoffs and companies from the broader
community. 


TEC provides services in three broad areas: client business development,
technology commercialization, and entrepreneur development. 


TEC's approx. 100 active clients are an outstanding group of companies: in the
last two years they have generated $180M in revenue, raised $85M in financing
and funding, invested $49M in R&D, grown both revenue and employment by 25%, and
employ approx. 1100 people in the region. In addition, TEC has assisted in the
creation of 7 spinoffs from the University in the last two years. 


In 2013 TEC Edmonton was identified by the Scandinavian UBI University Business
Incubator Index as the 17th best university business incubator in the world -
and the best in Canada.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Megan Lee, Ph.D.,MBA
Director, Corporate Affairs, Planning and Development
Ceapro Inc.
780.917.8394
mlee@ceapro.com
www.ceapro.com
Ceapro (TSXV:CZO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024